Page 468 - Binder2

• Last longer in the body—reducing the need for
frequent monitoring, escalation, or expensive
backups.

This is the model the Global South needs—not because it’s
cheaper, but because it’s resilient.

Redesigning Access Around Persistence

Global biologic equity will not be achieved through charity,
licensing, or tech transfer alone. It requires redefining
access itself.

Access isn’t just about affordability. It’s about:

• Predictability: Will the drug work for more than
six months?
• Simplicity: Can it be delivered without IV training
or sterile facilities?
• Immunological fit: Is it less likely to be rejected in
a diverse immunogenetic population?

To make biologics globally viable, we must invest in
therapies that:

• Are immunologically quiet, not just biochemically
potent.
• Integrate with local health systems, not impose
foreign logistics.
• Empower governments, NGOs, and communities
to produce and distribute treatments sustainably.

466